QUERCETIN POTENTIATES THE EFFECT OF ADRIAMYCIN IN A MULTIDRUG-RESISTANT MCF-7 HUMAN BREAST-CANCER CELL-LINE - P-GLYCOPROTEIN AS A POSSIBLE TARGET

被引:257
作者
SCAMBIA, G
RANELLETTI, FO
PANICI, PB
DEVINCENZO, R
BONANNO, G
FERRANDINA, G
PIANTELLI, M
BUSSA, S
RUMI, C
CIANFRIGLIA, M
MANCUSO, S
机构
[1] UNIV CATTOLICA SACRO CUORE, DEPT GYNECOL, I-00168 ROME, ITALY
[2] UNIV CATTOLICA SACRO CUORE, DEPT HISTOL, ROME, ITALY
[3] UNIV CATTOLICA SACRO CUORE, DEPT PATHOL, ROME, ITALY
[4] UNIV CATTOLICA SACRO CUORE, DEPT HEMATOL, ROME, ITALY
[5] ISS ROME, DEPT IMMUNOL, ROME, ITALY
关键词
QUERCETIN; ADRIAMYCIN; MULTIDRUG RESISTANCE; HUMAN BREAST CANCER CELLS;
D O I
10.1007/BF00685655
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
This study demonstrates that the flavonoid quercetin (Q), a plant-derived compound with low toxicity in vivo, greatly potentiates the growth-inhibitory activity of Adriamycin (ADR) on MCF-7 ADR-resistant human breast cancer cells. The effect of Q was dose-dependent at concentrations ranging between 1 and 10 mu M. Since ADR resistance in these cells is associated with the expression of high levels of P-glycoprotein (Pgp), we evaluated the effect of Q and related flavonoids of Pgp activity in cytofluorographic efflux experiments with the fluorescent dye rhodamine 123 (Rh 123). Our results indicate that Q and 3-OMe Q (3',4',7-trimethoxyquercetin) but not the 3-rhamnosylglucoside of Q (rutin) inhibit the Pgp pump-efflux activity in a dose-related manner. Moreover, 10 mu M Q reduces the expression of the immunoreactive Pgp in MCF-7 ADR-resistant cells as evaluated by cytofluorimetric assay. In conclusion, these findings provide a further biological basis for the potential therapeutic application of Q as an anticancer drug either alone or in combination with ADR in multidrug-resistant breast tumor cells.
引用
收藏
页码:459 / 464
页数:6
相关论文
共 42 条
  • [1] Adrian L. H., 1992, ACTA ONCOL, V31, P205
  • [2] CIANFRIGLIA M, 1994, INT J CANCER, V56, P153
  • [3] REVERSAL OF ADRIAMYCIN RESISTANCE BY LONIDAMINE IN A HUMAN BREAST-CANCER CELL-LINE
    CITRO, G
    CUCCO, C
    VERDINA, A
    ZUPI, G
    [J]. BRITISH JOURNAL OF CANCER, 1991, 64 (03) : 534 - 536
  • [4] PHARMACOLOGICAL AND SUPRAPHARMACOLOGICAL CONCENTRATIONS OF BOTH 17-BETA-ESTRADIOL AND TAMOXIFEN REDUCE THE MEMBRANE FLUIDITY OF MCF-7 AND MDA-MB-436 HUMAN-BREAST CANCER-CELLS
    CLARKE, R
    VANDENBERG, HW
    NELSON, J
    MURPHY, RF
    [J]. BIOCHEMICAL SOCIETY TRANSACTIONS, 1987, 15 (02) : 243 - 244
  • [5] ADVERSE INTERACTIONS BETWEEN CYTO-TOXIC DRUGS AND HORMONAL AGENTS IN HUMAN-BREAST CANCER-CELLS
    CLARKE, R
    VANDENBERG, HW
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (10) : 1580 - 1581
  • [6] MULTIDRUG RESISTANCE ACTIVITY IN HUMAN-LYMPHOCYTES
    COON, JS
    WANG, YZ
    BINES, SD
    MARKHAM, PN
    CHONG, ASF
    GEBEL, HM
    [J]. HUMAN IMMUNOLOGY, 1991, 32 (02) : 134 - 140
  • [7] DEFFIE AM, 1989, CANCER RES, V49, P58
  • [8] DEFFIE AM, 1988, CANCER RES, V48, P3595
  • [9] TOREMIFENE - PHARMACOLOGIC AND PHARMACOKINETIC BASIS OF REVERSING MULTIDRUG RESISTANCE
    DEGREGORIO, MW
    FORD, JM
    BENZ, CC
    WIEBE, VJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (09) : 1359 - 1364
  • [10] EFFERTH T, 1989, ANTICANCER RES, V9, P1633